IntelliPharmaCeutics Intl (IPCI) Earns Daily Media Impact Score of -0.04
News articles about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) have trended somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a news impact score of -0.04 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.724858048585 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- IntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- IntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC Wainwright (americanbankingnews.com)
- Maxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price Target (americanbankingnews.com)
- Intellipharmaceutics (IPCI) Announced Completed Meetings with … – StreetInsider.com (streetinsider.com)
- Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program (finance.yahoo.com)
A number of brokerages have recently commented on IPCI. HC Wainwright set a $3.00 price target on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Monday. Maxim Group set a $2.00 price target on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Friday. Finally, Zacks Investment Research downgraded shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $2.53.
WARNING: “IntelliPharmaCeutics Intl (IPCI) Earns Daily Media Impact Score of -0.04” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/13/intellipharmaceutics-intl-ipci-earns-daily-media-impact-score-of-0-04.html.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.